PDX Model Cohort
Breast Cancer PDX Models
Advance your Breast Cancer drug development research using an extensive bank of meticulously curated Breast Cancer PDX models directly established from patient tumors.
Summary
Champions Oncology has established a large cohort of patient breast cancer PDX models, with 121* models available to scientists for oncology research and drug development. These models are derived from patients with late-stage, primary, metastatic, and local metastatic tumors while retaining critical molecular features and alterations, making them therapeutically relevant.
(*Model numbers fluctuate as our dataset continuously evolves.)
Access to one of the largest bank of breast cancer models with clinically relevant molecularand pathological characteristics on the market.
Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics, and Phosphoproteomics.
Includes models pretreated with advanced therapies like Tamoxifen, Carboplatin, Docetaxel, Trastuzumab, and more.
Clinically Relevant Models
Living & diverse bank of clinically relevant models that correlate with clinical outcomes
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses